VERTEX PHARMACEUTICALS INC / MA (VRTX) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
	8-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Revenues:
Product revenues, net	8,930.7	7,574.4	6,205.7	4,162.8	3,047.6	2,488.7	1,702.2	1,032.3
Product revenues, net growth	17.9%	22.1%	49.1%	36.6%	22.5%	46.2%	64.9%	77.9%
Costs and expenses:
Research and development expenses	2,540.3	3,051.1	1,829.5	1,754.5	1,416.5	1,324.6	1,047.7	995.9
Selling, general and administrative expenses	944.7	840.1	770.5	658.5	557.6	496.1	432.8	376.6
Total costs and expenses	9,304.1	9,587.7	3,349.4	2,965.3	2,412.4	2,365.4	1,692.2	1,499.2
Income (loss) from operations	4,307.4	2,782.1	2,856.3	1,197.5	635.2	123.2	9.9	-466.9
Operating margin	48.2%	36.7%	46.0%	28.8%	20.8%	5.0%	0.6%	-45.2%
Interest expense	89.8	-61.5	-58.2	5.2	-34.1	-57.6	-81.4	-84.2
Other (expense) income, net	164.8	4.9	296.6	192.2	-0.8	-81.4	4.1	-6.7
Income (loss) before provision for (benefit from) income taxes		2,730.4	3,116.9	1,394.9
Provision for (benefit from) income taxes	910.4	388.3	405.2	218.1	-1,486.9	-107.3	16.7	30.4
Net income	3,322.0	2,342.1	2,711.7	1,176.8	2,096.9	263.5	-112.1	-556.3

Net income per common share:
Basic (in dollars per share)	$12.97	$9.09	$10.44	$4.58	$8.24	$1.06	($0.46)	($2.31)
Diluted (in dollars per share)	$12.82	$9.01	$10.29	$4.51	$8.09	$1.04	($0.46)	($2.31)

Shares used in per share calculations:
Basic (in shares)	256.1	257.7	259.8	256.7	254.3	248.9	244.7	241.3
Diluted (in shares)	259.1	259.9	263.4	260.7	259.2	253.2	244.7	241.3